GLP-1 Drugs and Healthy Habits Together Cut Major Cardiovascular Events by 43% in Diabetes Patients

Combining GLP-1 receptor agonist drugs with adherence to healthy lifestyle habits reduced the risk of major adverse cardiovascular events by 43 percent among adults with type 2 diabetes, compared to people who used neither the drugs nor the habits. That is the headline finding from a large observational cohort study published February 25 in The Lancet Diabetes and Endocrinology, led by researchers at Harvard T.H. Chan School of Public Health and the Department of Veterans Affairs Boston Healthcare System.

The study is among the first to systematically examine the combined effects of GLP-1 drugs and lifestyle on cardiovascular outcomes, rather than treating the two as alternative strategies. The data suggest they are not alternatives - they are additive, and the magnitude of benefit from lifestyle habits is larger than the drug effect alone.

The numbers

The study drew on data from more than 98,000 adults with type 2 diabetes and no prior cardiovascular disease, using records from the VA Million Veteran Program spanning 2011 to 2023. The major adverse cardiovascular events tracked were non-fatal stroke, non-fatal heart attack, and cardiovascular death.

More than 13,000 of the participants used a GLP-1 receptor agonist. Healthy lifestyle was measured across eight domains: healthy diet, regular exercise, not smoking, restful sleep, minimal alcohol intake, good stress management, social connection, and no opioid use disorder.

The results stratified clearly by both factors. GLP-1 use alone was associated with a 16 percent lower MACE risk. Adhering to all eight healthy lifestyle habits alone was associated with a 60 percent lower risk. Combining GLP-1 use with adherence to six to eight habits produced the 43 percent lower risk compared to those with neither - a comparison that captures the combined effect over a realistic clinical scenario.

What the findings mean for clinical practice

The persistence of the lifestyle signal alongside GLP-1 use has direct implications for how these drugs are prescribed and monitored in practice. GLP-1 receptor agonists, including semaglutide and liraglutide, have become among the most prescribed medications globally for type 2 diabetes and obesity. There is risk that their availability will reduce clinical emphasis on lifestyle counseling - that drugs will be seen as replacing behavioral changes rather than enhancing them.

Corresponding author Frank Hu, Fredrick J. Stare Professor of Nutrition and Epidemiology and chair of Harvard's Department of Nutrition, put the finding bluntly: "Even in the era of highly effective GLP-1 pharmacotherapy, lifestyle habits remain central to diabetes management and cardiovascular risk reduction."

Limitations

The study was observational, meaning it cannot establish causation with the certainty of a randomized trial. Residual confounding by socioeconomic status and other unmeasured factors is possible, though the researchers controlled for a range of demographic and health variables. The study population was primarily white male veterans, which may limit generalizability - though the researchers note that overall findings were consistent across racial and ethnic groups and between men and women. Self-reported lifestyle data introduces measurement error. The exact mechanisms through which the combination produces greater risk reduction than either factor alone were not assessed in this study design.

These limitations do not undermine the core message. The finding that lifestyle benefits remain substantial even when controlling for GLP-1 use - and that the two together outperform either alone - has direct relevance for clinical guidelines, patient counseling, and health policy in a period when new diabetes drugs are generating justifiable excitement.